Table 1.
Year | Type of Cancer | Number of samples | In-vivo study (Yes/No) | CHIP Expression | Reference |
---|---|---|---|---|---|
2010 | Breast cancer | 160 | No | ↓ | 375 |
2011 | Breast cancer | 183 | No | ↓ | 392 |
Glioma | 40 | Yes | ↑ | 399 | |
2012 | Gastric cancer | 53 | No | ↓ | 395 |
2013 | Esophageal squamous cell carcinoma | 234 | No | No change | 389 |
Gastric cancer | 640 | Yes | ↓ | 396 | |
Gallbladder carcinoma | 78 | No | ↑ | 390 | |
Colorectal cancer | 320 | No | ↓ | 364 | |
2015 | HBV-hepatocellular carcinoma | 79 | No | ↑ | 400 |
Human renal cell carcinoma | 304 | Yes | ↓ | 397 | |
Human renal cancer | 12 | Yes | ↓ | 342 | |
Gastric cancer | 164 | No | ↓ | 58 | |
2016 | Non-small cell lung cancer | 106 | Yes | ↓ | 398 |
Postmenopausal breast cancer | 272 | No | ↑ | 394 | |
2017 | Head and neck cancer | 101 | Yes | ↑ | 401 |
2018 | Colorectal cancer | 93 | Yes | ↑ | 402 |
Prostate cancer | 90 | No | ↑ | 391 | |
2019 | Gastric cancer | 100 | Yes | ↓ | 361 |
Breast cancer | 128 | Yes | ↓ | 393 |